Skip to main content
SpringerLink
Log in

Adding metyrapone to chemotherapy plus mitotane for Cushing’s syndrome due to advanced adrenocortical carcinoma

  • Research Letter
  • Published:
Endocrine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. M. Terzolo, F. Daffara, A. Ardito, B. Zaggia, V. Basule, L. Ferrari, A. Berruti, Management of adrenal cancer: a 2013 update. J. Endocrinol. Invest. 37, 207–217 (2014). https://doi.org/10.1007/s40618-013-0049-2

    Article  PubMed  CAS  Google Scholar 

  2. A. Berruti, M. Fassnacht, H. Haak et al. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur. Urol. 65, 832–838 (2014). https://doi.org/10.1016/j.eururo.2013.11.006

    Article  PubMed  CAS  Google Scholar 

  3. P. Malandrino, A. Al Ghuzlan, M. Castaing, J. Young, B. Caillou, J.P. Travagli, D. Elias, T. de Baere, C. Dromain, A. Paci, P. Chanson, M. Schlumberger, S. Leboulleux, E. Baudin, Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr. Relat. Cancer. 17, 797–807 (2010). https://doi.org/10.1677/ERC-09-0341

    Article  PubMed  CAS  Google Scholar 

  4. A. Berruti, E. Baudin, H. Gelderblom, H.R. Haak, F. Porpiglia, M. Fassnacht, G. Pentheroudakis; ESMO Guidelines Working Group., Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23, vii131–vii138 (2012). https://doi.org/10.1093/annonc/mds231

    Article  PubMed  Google Scholar 

  5. S. Hahner, M. Fassnacht, Mitotane for adrenocortical carcinoma treatment. Curr. Opin. Investig. Drugs. 6(4), 386–394 (2005)

    PubMed  CAS  Google Scholar 

  6. I.G. Hermsen, M. Fassnacht, M. Terzolo et al. Plasma concentrations of o,p’DDD, o,p’DDA, and o,p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin 96, 1844–1851 (2011). https://doi.org/10.1210/jc2010-2676

    Article  CAS  Google Scholar 

  7. M. Terzolo, A. Pia, A. Berruti, A. Osella Gm Alì, V. Carbone, E. Testa, L. Dogliotti, A. Angeli, Lowe-dose monitored mitotane treatment achieve the therapeutic range with manageable side effects in patients with adrenocortical cancer. J. Clin. Endocrinol. Metab. (2000). https://doi.org/10.1210/jcem.85.6.6619

  8. E. Daniel, S. Aylwin, O. Mustafa et al. Effectiveness of metyrapone in treating cushing’s syndrome: a retrospective multicenter study in 195 patients. J. Clin. Endocrinol. Metab. 100, 4146–4154 (2015). https://doi.org/10.1210/jc.2015-2616

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. J.A. Verhelst, P.J. Trainer, T.A. Howlett, L. Perry, L.H. Rees, A.B. Grossman, J.A. Wass, G.M. Besser, Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin. Endocrinol. 35(2), 169–178 (1991)

    Article  CAS  Google Scholar 

  10. M. Kroiss, M. Quinkler, W.K. Lutz, B. Allolio, M. Fassnacht, Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin. Endocrinol. 75, 585–591 (2011). https://doi.org/10.1111/j.13652265.2011.04214.x

    Article  CAS  Google Scholar 

  11. Metyrapone. In: DRUGDEX® System [Internet database]. (Thomson Micromedex, Greenwood Village, Colo). Updated periodically, http://www.micromedexsolutions.com. Accessed 18 Jan 2016

  12. I. Veytsman, L. Nieman, T. Fojo, Management of endocrine manifestations and the use of mitotane as chemotherapeutic agent for adrenocortical carcinoma. J. Clin. Oncol. 27, 4619–4629 (2009). https://doi.org/10.1200/JCO.2008.17.2775

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. S.P. Rajeev, S. McDougall, M. Terlizzo, D. Palmer, C. Daousi, D.J. Cuthbertson, Evolution in functionality of a metastatic pancreatic neuroendocrine tumor (pNET) causing Cushing’s syndrome: treatment response with chemotherapy. BMC Endocr. Disord. 14, 70 (2014). https://doi.org/10.1186/1472-6823-14-70

    Article  PubMed  PubMed Central  Google Scholar 

  14. M. Wojcik, A. Kalicka-Kasperczyk, T. Luszawska-Kutrzeba, W. Balwierz, J.B. Starzyk, The first description of metyrapone use in severe Cushing Syndrome due to ectopic ACTH secretion in an infant with immature sacrococcygeal teratoma. Case Report. Neuro Endocrinol. Lett. 36(7), 653–655 (2015)

    PubMed  CAS  Google Scholar 

  15. R.E. Galinsky, E.B. Nelson, D.E. Rollins, Pharmacokinetic consequences and toxicologic implications of metyrapone-induced alterations of acetaminophen elimination in man. Eur. J. Clin. Pharmacol. 33(4), 391–396 (1987)

    Article  PubMed  CAS  Google Scholar 

  16. A. Berruti, M. Terzolo, P. Sperone et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr. Relat. Cancer 12(3), 657–666 (2005). https://doi.org/10.1677/ec.1.01025

    Article  PubMed  CAS  Google Scholar 

  17. M. Fasssancht, M. Terzolo, B. Allolio et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189–2197 (2012). https://doi.org/10.1056/NEJMoal1200966

    Article  Google Scholar 

Download references

Acknowledgements

Grant IG 2015-17678 from Associazione Italiana per la Ricerca sul Cancro (AIRC) to MT. Private grant from the amateur dramatics group “Attori non per caso”, parish church of Collio Valtrompia (Brescia) to BL.

Funding

This study was funded by Associazione Italiana per la Ricerca sul Cancro (AIRC), grant n. IG 2015-17678 to MT and by a private grant from the amateur dramatics group “Attori non per caso”, parish church of Collio Valtrompia (Brescia) to BL.

Author information

Authors and Affiliations

  1. Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy

    Mélanie Claps, Sara Cerri, Salvatore Grisanti, Barbara Lazzari, Vittorio Ferrari, Elisa Roca & Alfredo Berruti

  2. Internal Medicine 1, Department of Clinical and Biological Sciences, S. Luigi Hospital, University of Turin, Torino, Italy

    Paola Perotti & Massimo Terzolo

  3. Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

    Sandra Sigala

Authors
  1. Mélanie Claps
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara Cerri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salvatore Grisanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barbara Lazzari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vittorio Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elisa Roca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paola Perotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Massimo Terzolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sandra Sigala
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Alfredo Berruti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alfredo Berruti.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Claps, M., Cerri, S., Grisanti, S. et al. Adding metyrapone to chemotherapy plus mitotane for Cushing’s syndrome due to advanced adrenocortical carcinoma. Endocrine 61, 169–172 (2018). https://doi.org/10.1007/s12020-017-1428-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-017-1428-9

Search

Navigation